We recently published a list of Jim Cramer Discusses These 11 Stocks & President Trump’s Sovereign Wealth Fund. In this ...

We recently compiled a list of the Jim Cramer Discussed These 12 Stocks Amidst The DeepSeek AI Selloff. In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands ...

Morgan Stanley initiated coverage of Novo Nordisk (NVO) with an Equal Weight rating and DKK 700 price target The firm says near-term U.S.

In a report released today, Florent Cespedes from Bernstein maintained a Hold rating on Novo Nordisk (0QIU – Research Report), with a price ...

LONDON/SAN FRANCISCO, Feb 4 (Reuters) - Novo Nordisk (NOVOb.CO), opens new tab is under pressure from investors for more information about its next-generation obesity drug candidate CagriSema amid ...

LONDON, Jan 30 (Reuters) - Novo Nordisk (NOVOb.CO), opens new tab said on Thursday it has not yet posted details about a new trial of its experimental next-generation obesity drug CagriSema ...

With sales of Novo Nordisk’s obesity blockbuster Wegovy ... The success of both Wegovy and Ozempic is due in no small part to the manufacturing expansion campaign Novo has been carrying out ...

Novo Nordisk reported strong data for its next-gen anti-obesity medicine. The Danish company has an excellent weight loss drug pipeline. But it's also diversifying its lineup and offering other perks.

Danish drugmaker Novo Nordisk on Wednesday posted another quarter of rapid profit growth, though the story for once wasn’t its wildly popular weight-loss drugs. Novo Nordisk said its fourth ...

Drugmakers have poured small fortunes into the development of weight loss medicines in the past few years in attempts to lead this lucrative and fast-growing market. However, Novo Nordisk (NYSE ...

Monlunabant, formerly INV-202, came from Novo Nordisk’s 2023 acquisition of Inversago Pharma. The Canadian company designed this small molecule to preferentially target CB1 receptors in the ...